Clinical trial NCT00057811 (phase 2, status: completed)
Conditions: childhood burkitt lymphoma, childhood diffuse large cell lymphoma, childhood immunoblastic large cell lymphoma, stage i childhood large cell lymphoma, stage i childhood small noncleaved cell lymphoma, stage ii childhood large cell lymphoma, stage ii childhood small noncleaved cell lymphoma, stage iii childhood large cell lymphoma, stage iii childhood small noncleaved cell lymphoma, stage iv childhood large cell lymphoma, stage iv childhood small noncleaved cell lymphoma, untreated childhood acute lymphoblastic leukemia
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S, C83.57, C83.50, C91.01, C91.02, C83.52, C83.56, C83.53
Drugs: doxorubicin hydrochloride, cyclophosphamide, methotrexate, rasburicase, leucovorin calcium, prednisone, methylprednisolone, cytarabine, etoposide, vincristine sulfate, hydrocortisone sodium succinate
SMILES: COC1=CC=CC2=C1C(=O)C1=C(O)C3=C(C[C@](O)(C[C@@H]3O[C@H]3C[C@H](N)[C@H](O)[C@H](C)O3)C(=O)CO)C(O)=C1C2=O, ClCCN(CCCl)P1(=O)NCCCO1, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, NC1=NC(=O)C2=C(NC[C@H](CNC3=CC=C(C=C3)C(=O)N[C@@H](CCC(O)=O)C(O)=O)N2C=O)N1, [H][C@@]12CC=C(C3=CC=CN=C3)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC=C2C[C@@H](O)CC[C@]12C, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C, ClCCN(CCCl)P1(=O)NCCCO1, OCCOCCN1CCN(CC1)C(C1=CC=CC=C1)C1=CC=C(Cl)C=C1, CC[C@]1(O)C[C@@H]2CN(C1)CCC1=C(NC3=CC=CC=C13)[C@@](C2)(C(=O)OC)C1=C(OC)C=C2N(C=O)[C@@H]3[C@]4(CCN5CC=C[C@](CC)([C@@H]45)[C@@H](OC(C)=O)[C@]3(O)C(=O)OC)C2=C1, [H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[C@H](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)CC[C@]12C
Eligibility criteria:

        Inclusion Criteria:

          -  Newly diagnosed mature B-lineage (CD20-positive) leukemia or lymphoma by the REAL
             classification of 1 of the following subtypes:

               -  Diffuse large cell lymphoma

               -  Burkitt's lymphoma

               -  High-grade B-cell lymphoma (Burkitt-like)

          -  No B-cell anaplastic large cell Ki-1 positive lymphomas and B-lymphoblastic lymphomas

          -  One of the following FAB prognostic groups:

               -  Group B (intermediate risk)

               -  Group C (high risk)

                    -  Bone marrow involvement with at least 25% blasts and/or CNS involvement
                       meeting 1 or more of the following criteria:

                         -  Any L3 blasts in cerebrospinal fluid

                         -  Cranial nerve palsy (if not explained by extracranial tumor)

                         -  Clinical spinal cord compression

                         -  Isolated intracerebral mass

                         -  Parameningeal extension (cranial and/or spinal)

          -  Hepatitis B status known

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception during and for 6 months after study
             participation

          -  No known history of congenital immune deficiency and/or laboratory evidence of
             acquired immune deficiency

          -  No known G6PD deficiency (if receiving rasburicase)

          -  No prior malignancies treated with systemic chemotherapy with alkylator or
             anthracycline therapy

          -  No prior chemotherapy

          -  At least 1 week since prior steroids except emergency steroids initiated within 72
             hours of study entry

          -  No prior radiotherapy except emergency radiotherapy initiated within 72 hours of study
             entry

          -  No concurrent radiotherapy

          -  No prior solid organ transplantation